These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35538399)

  • 1. Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    He Y; Shen Q; Fu W; Wang H; Song G
    Prostate; 2022 Aug; 82(11):1125-1132. PubMed ID: 35538399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate magnetic resonance imaging-targeted biopsy global grade correlates better than highest grade with prostatectomy grade.
    Ren J; Melamed J; Taneja SS; Wysock JS; Huang WC; Lepor H; Deng FM
    Prostate; 2023 Mar; 83(4):323-330. PubMed ID: 36461793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Method for Reporting Prostate Cancer Grade in MRI-targeted Biopsies.
    Deng FM; Isaila B; Jones D; Ren Q; Kyung P; Hoskoppal D; Huang H; Mirsadraei L; Xia Y; Melamed J
    Am J Surg Pathol; 2022 Jan; 46(1):44-50. PubMed ID: 34115670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel biopsy scheme for prostate cancer: targeted and regional systematic biopsy.
    He Y; Fan Y; Song H; Shen Q; Ruan M; Chen Y; Li D; Li X; Liu Y; Zhang K; Zhang Q
    BMC Urol; 2024 Apr; 24(1):85. PubMed ID: 38614971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological findings at radical prostatectomy of biopsy naïve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling.
    Luzzago S; Petralia G; Maresca D; Sabatini I; Cordima G; Brescia A; Verweij F; Garelli G; Mistretta FA; Cioffi A; Pricolo P; Alessi S; Ferro M; Matei DV; Renne G; de Cobelli O; Musi G
    Urol Oncol; 2020 Dec; 38(12):929.e11-929.e19. PubMed ID: 32600928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade.
    Scuderi S; Pellegrino F; Tin A; Beech BB; Gandaglia G; Stabile A; Eastham JA; Montorsi F; Briganti A; Vickers AJ
    Eur Urol Focus; 2024 May; 10(3):486-488. PubMed ID: 37739916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    World J Urol; 2020 Mar; 38(3):663-671. PubMed ID: 31197523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies.
    Ploussard G; Beauval JB; Lesourd M; Almeras C; Assoun J; Aziza R; Gautier JR; Loison G; Portalez D; Salin A; Tollon C; Soulié M; Malavaud B; Roumiguié M
    Urology; 2020 Mar; 137():126-132. PubMed ID: 31899229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination MRI-targeted and systematic prostate biopsy may overestimate gleason grade on final surgical pathology and impact risk stratification.
    Yu A; Yamany T; Mojtahed A; Hanna N; Nicaise E; Harisinghani M; Wu CL; Dahl DM; Wszolek M; Blute ML; Feldman AS
    Urol Oncol; 2022 Feb; 40(2):59.e1-59.e5. PubMed ID: 34544650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance of "Case Level" Global, Highest, and Largest Volume Cancer Grade Group on Needle Biopsy Versus Grade Group on Radical Prostatectomy.
    Trpkov K; Sangkhamanon S; Yilmaz A; Medlicott SAC; Donnelly B; Gotto G; Shea-Budgell M
    Am J Surg Pathol; 2018 Nov; 42(11):1522-1529. PubMed ID: 30080706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies.
    Manceau C; Fromont-Hankard G; Beauval JB; Lesourd M; Almeras C; Bajeot AS; Gautier JR; Soulié M; Loison G; Salin A; Tollon C; Malavaud B; Roumiguié M; Ploussard G
    World J Urol; 2021 Sep; 39(9):3315-3321. PubMed ID: 33609168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gleason Grade Group Concordance between Preoperative Targeted Biopsy and Radical Prostatectomy Histopathologic Analysis: A Comparison Between In-Bore MRI-guided and MRI-Transrectal US Fusion Prostate Biopsies.
    Costa DN; Cai Q; Xi Y; Recchimuzzi DZ; Subramanian N; Bagrodia A; Rofsky NM; Roehrborn CG; Hornberger B; Shah RB; Goldberg K; Diaz de Leon A; Pedrosa I
    Radiol Imaging Cancer; 2021 Mar; 3(2):e200123. PubMed ID: 33817652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
    Rahota RG; Diamand R; Malavaud B; Fiard G; Descotes JL; Peltier A; Beauval JB; Roumeguère T; Roumiguié M; Albisinni S; Ploussard G
    BJU Int; 2022 May; 129(5):621-626. PubMed ID: 34358405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-Fusion Targeted vs. Systematic Prostate Biopsy-How Does the Biopsy Technique Affect Gleason Grade Concordance and Upgrading After Radical Prostatectomy?
    Rührup J; Preisser F; Theißen L; Wenzel M; Roos FC; Becker A; Kluth LA; Bodelle B; Köllermann J; Chun FKH; Mandel P
    Front Surg; 2019; 6():55. PubMed ID: 31620444
    [No Abstract]   [Full Text] [Related]  

  • 15. Defining the optimal method for reporting prostate cancer grade and tumor extent on magnetic resonance/ultrasound fusion-targeted biopsies.
    Gordetsky JB; Schultz L; Porter KK; Nix JW; Thomas JV; Del Carmen Rodriguez Pena M; Rais-Bahrami S
    Hum Pathol; 2018 Jun; 76():68-75. PubMed ID: 29551676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen.
    Radtke JP; Schwab C; Wolf MB; Freitag MT; Alt CD; Kesch C; Popeneciu IV; Huettenbrink C; Gasch C; Klein T; Bonekamp D; Duensing S; Roth W; Schueler S; Stock C; Schlemmer HP; Roethke M; Hohenfellner M; Hadaschik BA
    Eur Urol; 2016 Nov; 70(5):846-853. PubMed ID: 26810346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Gleason Grading Group Upgrading in Low-Risk Prostate Cancer Patients From Transperineal Biopsy After Radical Prostatectomy.
    Zhou L; Xu LL; Zheng LL; Chen C; Xu L; Zeng JL; Li SY
    Acad Radiol; 2024 Jul; 31(7):2838-2847. PubMed ID: 38233258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentric study on accurate grading of prostate cancer with systematic and MRI/US fusion targeted biopsies: comparison with final histopathology after radical prostatectomy.
    Diamand R; Oderda M; Al Hajj Obeid W; Albisinni S; Van Velthoven R; Fasolis G; Simone G; Ferriero M; Roche JB; Piechaud T; Pastore A; Carbone A; Fiard G; Descotes JL; Marra G; Gontero P; Altobelli E; Papalia R; Kumar P; Eldred-Evans D; Giacobbe A; Muto G; Lacetera V; Beatrici V; Roumeguere T; Peltier A
    World J Urol; 2019 Oct; 37(10):2109-2117. PubMed ID: 30652213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Gaffney CD; Tin AL; Fainberg J; Fine S; Jibara G; Touijer K; Eastham J; Scardino P; Laudone V; Vickers AJ; Ehdaie B
    Cancer; 2023 Dec; 129(23):3790-3796. PubMed ID: 37584213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of perilesional and multiparametric resonance imaging-targeted biopsies to reduce the risk of upgrading at radical prostatectomy pathology: A retrospective monocentric study.
    Diamand R; Hollans M; Lefebvre Y; Sirtaine N; Limani K; Hawaux E; Abou Zahr R; Mattlet A; Albisinni S; Roumeguère T; Peltier A
    Urol Oncol; 2022 May; 40(5):192.e11-192.e17. PubMed ID: 35236622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.